Accelerating Access for Patients Act of 2022

Bill 117 HR 6996, also known as the Accelerating Access for Patients Act of 2022, aims to streamline the process for patients to access potentially life-saving treatments and therapies. The bill focuses on reducing barriers and delays in the approval and availability of new medical products.

One key aspect of the bill is the establishment of a new program within the Food and Drug Administration (FDA) called the Patient Access Program. This program will prioritize the review and approval of certain medical products that have the potential to address unmet medical needs or provide significant benefits to patients. The goal is to expedite the availability of these products to patients who need them most.

Additionally, the bill includes provisions to enhance communication and collaboration between the FDA, healthcare providers, and patients. This includes requirements for the FDA to provide timely updates on the status of product reviews and approvals, as well as increased transparency in the decision-making process. Overall, the Accelerating Access for Patients Act of 2022 seeks to improve patient access to innovative medical treatments and therapies by streamlining the regulatory process and promoting greater collaboration between stakeholders.